DSIP stands for delta sleep-inducing peptide. It was isolated in 1977 from the cerebral blood of rabbits and immediately hailed as a natural sleep factor. Almost fifty years later the situation is surprising: the peptide has a known sequence and can be synthesised, yet neither its gene nor the receptor it is supposed to act on has ever been found. The human studies are old, small and contradictory, and the two claims repeated most often — that DSIP lowers cortisol and that it raises growth hormone — have been tested in people and were not confirmed. What follows, in order: what has been shown, what has been refuted and what remains a puzzle.
What DSIP is
It is a nonapeptide, a chain of nine amino acids. Guy Schoenenberger and Marcel Monnier found it in Basel by drawing blood from the cerebral veins of rabbits in which slow-wave sleep had been induced. The isolated substance was synthesised and infused into the brain ventricles of other rabbits. Of the nine peptides tested — DSIP itself, five of its possible fragments, two altered versions and one short related peptide — only the original nonapeptide significantly enhanced delta waves and sleep spindles on the EEG. The experiment covered 58 rabbits and was run under double-blind conditions.
How it is meant to work — and why we do not know
Here lies the heart of the problem. An ordinary peptide works like this: it attaches to a “switch” on the cell surface (a receptor) and triggers a chain of events inside. In the case of DSIP no such switch has ever been found. Nor has the gene that would encode the peptide, nor the precursor protein it would be made from.
A 2006 review in the Journal of Neurochemistry calls this an unresolved riddle outright and states that the hypothesis of DSIP as a sleep factor is very poorly documented. The authors point to an awkward detail: the substance that DSIP assays recognise in tissue accumulates in hypothalamic nuclei that happen not to govern sleep. They suggest that what the assays detect may be a different, still undescribed peptide of similar structure. They add an observation that spoils the simple story: in their own work, slow-wave sleep in rabbits and rats was enhanced by certain artificial analogues of DSIP, but not by DSIP itself.
Human data — sleep
There are several human studies, all from the 1980s and 1990s, all small, and they do not agree with one another. They cannot be averaged, so we give them separately.
A positive result. In a 1987 study, fourteen patients with severe chronic insomnia received DSIP or placebo for seven consecutive nights, double-blind, with full polysomnographic recording. The author reports clear improvement in sleep after the first dose and greater improvement with repeated ones, with night-sleep efficiency and daytime rest said to reach the level of healthy controls. Daytime alertness and mental performance rose significantly. This is the only trial with so clearly positive an outcome, and it comes from a single author with no independent replication.
A neutral result. In that same year another group gave DSIP intravenously over four nights in a crossover design against placebo. The number of awakenings, waking time and sleep-onset latency fell and total sleep time rose — but none of those differences was significant against baseline nights or placebo, and where a difference from placebo did reach significance, it already existed before treatment. The authors concluded that sleep improvement under DSIP is of little clinical significance.
A weak result. The most carefully described study dates from 1992: sixteen patients with chronic insomnia, five nights in a sleep laboratory, double-blind with a placebo group. Sleep efficiency rose and sleep latency shortened on DSIP, but the authors themselves caution that the effects were weak and could in part be due to an incidental change in the placebo group. Subjective sleep quality did not change at all. Their conclusion: short-term treatment of chronic insomnia with DSIP is unlikely to bring major benefit.
Human data — hormones, or what was refuted
The most popular claim about DSIP is that it lowers cortisol, the stress hormone. This was checked twice in humans, with differing outcomes.
In a 1989 study, eleven healthy men received a single intravenous injection of DSIP or saline in a crossover design. The marker for ACTH — the hormone that drives cortisol release — was reduced for at least three hours. But the concentration of cortisol itself in blood stayed unchanged and declined along its normal daily rhythm; urinary cortisol did not differ either.
Six years later a group in Lubeck tested the question more rigorously: first in healthy men stimulated with CRH (a trigger for the stress axis), then in ten men during the natural midday hormone surge that follows a meal. In both settings the ACTH and cortisol responses after DSIP were virtually identical to placebo. The authors' conclusion is unambiguous: the data do not support an inhibitory effect of DSIP on ACTH and cortisol secretion in humans.
The second popular claim — that DSIP raises growth hormone — has also been tested. In a study of eight healthy women, DSIP changed neither the baseline levels of growth hormone and prolactin, nor their daily rhythm, nor their response to a standard stimulus (arginine). No effect across the board. If DSIP did anything to growth hormone, it could only be indirectly, by deepening the sleep during which that hormone is naturally released.
The puzzle of a lasting effect
One observation recurs across the studies and is genuinely odd. In the 1992 trial the peptide was given in the afternoon, and sleep was measured at night. In the 1987 trial the sleep improvement persisted into the first night after dosing ended, when patients were already receiving placebo. Peptides such as DSIP, meanwhile, disappear from the blood very quickly. If the effect is real, it cannot be the simple action of a molecule present in the blood at that moment; it would have to rest on some change locked into the machinery that regulates sleep. The honest answer, though, is different: with studies this small and this contradictory, it cannot be settled whether a lasting effect exists at all.
Safety and the limits of the evidence
The studies described reported no serious adverse effects, but that is not proof of safety: in total we are talking about a few dozen people, observed over a few nights, more than thirty years ago. DSIP is not an approved medicine anywhere in the world. The ClinicalTrials.gov registry holds not one trial in which DSIP is the administered intervention — the entire human record predates the era of mandatory trial registration.
Two further limitations. First, a large share of the sleep literature comes from a single author, while the other major branch of research, the Russian one, concerns mainly analogues rather than DSIP itself. Second, it is unknown what the peptide does outside sleep: since it is detected in hypothalamic nuclei unrelated to sleep, actions that nobody has measured cannot be ruled out. We deliberately give no methods of use and no doses.
The wider context
DSIP belongs to a group of short regulatory peptides studied mainly in the 1970s and 1980s, before large randomised trials became the standard. Epitalon, the pineal peptide, travelled a similar road, as did selank from the Russian school of regulatory peptides. What this family shares is a gulf between an abundance of laboratory work and a poverty of good clinical trials. DSIP is the extreme case: we have the sequence and fifty years of publications, and still no receptor, no gene and not one decisive human study.
Summary
DSIP is a nine-amino-acid peptide isolated in 1977 from the blood of sleeping rabbits, in which it enhanced slow waves on the EEG. In humans it was tested in a handful of small studies from the 1980s and 1990s: one showed clear improvement in sleep, two others improvement of no clinical significance or an effect at the edge of noise. The claims that it lowers cortisol and raises growth hormone were tested in people and were not confirmed. No receptor and no gene have been found, and newer clinical trials do not exist. The evidence is weak, old and contradictory — this is an object of research, not a proven way to improve sleep.
Sources
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193–197. PMID: 1299794. DOI: 10.1159/000118919. pubmed.ncbi.nlm.nih.gov/1299794
- Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. European Neurology. 1987;27(2):120–129. PMID: 3622582. DOI: 10.1159/000116143. pubmed.ncbi.nlm.nih.gov/3622582
- Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research. 1987;7(2):105–110. PMID: 3583493. pubmed.ncbi.nlm.nih.gov/3583493
- Bjartell A, Ekman R, Bergquist S, Widerlöv E. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology. 1989;14(5):347–355. PMID: 2554357. DOI: 10.1016/0306-4530(89)90004-8. pubmed.ncbi.nlm.nih.gov/2554357
- Späth-Schwalbe E, Schäfer A, Uthgenannt D, Born J, Fehm HL. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology. 1995;20(3):231–237. PMID: 7777652. DOI: 10.1016/0306-4530(94)00050-k. pubmed.ncbi.nlm.nih.gov/7777652
- Giusti M, Carraro A, Porcella E, et al. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology. 1993;18(1):79–84. PMID: 8475226. DOI: 10.1016/0306-4530(93)90057-r. pubmed.ncbi.nlm.nih.gov/8475226
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences of the USA. 1977;74(3):1282–1286. PMID: 265572. DOI: 10.1073/pnas.74.3.1282. pubmed.ncbi.nlm.nih.gov/265572
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303–309. PMID: 16539679. DOI: 10.1111/j.1471-4159.2006.03693.x. pubmed.ncbi.nlm.nih.gov/16539679
For in-vitro laboratory research only. It is not a human medicine and is not for treatment.